The missed expectation from Revised Schedule M specifically highlighted the need for a structured approach to CPV as part of the validation lifecycle.

Better GMP / Schedule M Approach

To better align with Schedule M expectations, manufacturers must adopt a structured CPV model that integrates ongoing performance monitoring into their quality systems. An improved approach includes:

• Automated Data Collection: Utilize real-time data collection tools to monitor CPPs and CQAs continuously.
• Statistical Process Control: Apply statistical methodologies to interpret data, identify trends, and mitigate risks proactively.
• Documentation Practices: Maintain comprehensive CPV records that demonstrate compliance, including deviation investigations and corrective actions.

Risk-Based Control Considerations

Risk management is integral to CPV, ensuring that all critical aspects of the process are evaluated systematically. Companies should conduct regular risk assessments to identify potential failure points in the manufacturing process, focusing on:

• Prioritizing CPPs and CQAs based on their impact on product quality.
• Implementing controls that mitigate identified risks and ensuring these controls are validated accordingly.
• Reviewing risks periodically as process changes occur or as data from CPV activities indicate a shift in process performance.

Documentation, Training and CAPA Strategy

Robust documentation is fundamental to CPV. All findings from continuous monitoring, along with training records for personnel involved in the CPV process, should be meticulously recorded. Additionally, a well-defined Corrective and Preventive Action (CAPA) strategy should be in place to address any discrepancies identified during CPV. The strategy should encompass:

• Identification of root causes for non-compliance.
• Implementation of corrective measures and tracking of their effectiveness.
• Regular audits of CPV documentation to ensure continuous improvement.

Inspection Relevance

From an inspection perspective, a robust CPV program can significantly enhance CDSCO inspection readiness. Inspectors will focus on:

• Evidencing the maturity of CPV practices.
• Reviewing data integrity and the reliability of output from monitoring systems.
• Assessing the effectiveness of CAPA in addressing past issues.

Building a strong CPV framework demonstrates an organization’s commitment to quality, thereby reducing the likelihood of compliance issues during inspections.

Evidence and Effectiveness Check

Evidence of effective CPV includes documented data from monitoring systems, trend analysis reports, and records of training sessions related to CPV practices. Effectiveness checks should be conducted to ensure that the implemented CPV controls are functioning as intended. Regular reviews should involve:

• Statistical analysis of data collected over time.
• Feedback mechanisms from operations to capture insights on CPV implementation.
• Updating SOPs to include latest findings and outcomes from CPV activities.

QA Review Questions

To ensure CPV practices align with Schedule M requirements, quality assurance professionals can consider the following questions:

• Are CPPs and CQAs clearly defined and documented for all processes?
• Is there a mechanism in place for real-time monitoring of critical parameters?
• How frequently is the CPV data reviewed and by whom?
• Are CAPA actions documented adequately following deviations in CPV data?
• Is staff trained effectively on the importance and execution of CPV?

Practical Example or Sample Wording

A practical example of CPV could illustrate the implementation in a tablet formulation process where temperature and humidity are monitored as CPPs. The documentation could include wording like:

Conclusion

The essence of Continued Process Verification within the framework of Revised Schedule M cannot be overstated. By proactively designing CPV strategies that integrate risk management, documentation, and ongoing training initiatives, pharmaceutical manufacturers can not only ensure compliance but also enhance their product quality and inspection readiness. The successful incorporation of CPV into the pharmaceutical validation lifecycle exemplifies a commitment to excellence in manufacturing practices, ultimately benefiting both the industry and consumers alike.